Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052648 · ClinicalTrials.gov registry record · Phase 1
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT02052648 is a Phase 1 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 160 participants.
The verdict
NCT02052648, a Phase 1 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combination with vaccine therapies.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- RADIATION Stereotactic Radiation
- DRUG Indoximod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052648
The ClinicalTrials.gov registry entry for NCT02052648 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT02052648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02052648 about?
NCT02052648 is a clinical study titled "Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors". In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combi...
What is the current status of trial NCT02052648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2014-03. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT02052648?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Stereotactic Radiation (RADIATION), Indoximod (DRUG).
Who is sponsoring clinical trial NCT02052648?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.